Live Breaking News & Updates on Clinical Development Centers

Stay updated with breaking news from Clinical development centers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024

/PRNewswire/ Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities. ....

United States , Los Angeles , Product Development Center , Prnewswire Transcenta Holding Limited , Transcenta Immune Tolerance Breaking Technology , Clinical Development Centers In Princeton , Group Headquarters , Translational Research Center , Holding Limited , Clinical Oncology Volume , Immune Tolerance Breaking Technology , Orphan Drug Designation , Manufacturing Facility , Clinical Development Centers , External Partnering Center , Suzhou Industrial ,

Transcenta Announces Collaboration with Agilent to Develop a Claudin18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial

Transcenta Announces Collaboration with Agilent to Develop a Claudin18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Paul Beresford , Caroline Germa , Los Angeles , Product Development Center , Clinical Development Centers , Transcenta Holding , Transcenta Immune Tolerance Breaking Technology , Global Medicine Development , Prnewswire Transcenta Holding Limited , Translational Research Center , Group Headquarters , Agilent Technologies , Holding Limited , Investigational Use , Performance Evaluation Only , Executive Vice President , Chief Medical , Immune Tolerance Breaking Technology , Orphan Drug Designation , Manufacturing Facility , External Partnering Center , Suzhou Industrial ,

Transcenta Unveils Updated Efficacy Data from Osemitamab (TST001) Plus CAPOX as First-Line Treatment for G/GEJ Cancer Study at ESMO 2023

Latest data reveals a 55% confirmed response rate, median duration of response (DoR) and median progression-free survival (PFS) of more than 12 months for all ....

United States , Caroline Germa , Los Angeles , Transcenta Holding , Transcenta Immune Tolerance Breaking Technology , Transcenta Holding Limited , Clinical Development Centers In Princeton , Translational Research Center , Product Development Center , Global Medicine Development , Group Headquarters , Executive Vice President , Chief Medical , Manageable Safety , Immune Tolerance Breaking Technology , Orphan Drug Designation , Manufacturing Facility , Clinical Development Centers , External Partnering Center , Suzhou Industrial ,

FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients

/PRNewswire/ Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in. ....

South Korea , United States , Los Angeles , Caroline Germa , Product Development Center , Transcenta Holding , Prnewswire Transcenta Holding Limited , Business Development Center , Clinical Development Centers In Princeton , Group Headquarters , Global Medicine Development , Translational Research Center , Transcenta Immune Tolerance Breaking Technology , Global Therapy , Current Standard , Holding Limited , Drug Evaluation , Transcenta Executive Vice President , Chief Medical , Cancer Statistics , Mortality Worldwide , Gastric Cancer Version , Immune Tolerance Breaking Technology , Orphan Drug Designation , Manufacturing Facility , Clinical Development Centers ,

Transcenta to Present Three Study Results at ESMO 2023

Transcenta to Present Three Study Results at ESMO 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Lin Shen , Xueming Qian , Los Angeles , Product Development Center , Prnewswire Transcenta Holding Limited , Translational Research Center , Group Headquarters , Business Development Center , Clinical Development Centers , Transcenta Holding , Transcenta Immune Tolerance Breaking Technology , European Society Of Medical Oncology , Suzhou Transcenta Therapeutics Co Ltd , Holding Limited , Medical Oncology , First Line Osemitamab , Study Transtar , Beijing Cancer , Exposure Response Analyses , Locally Advanced , Metastatic Solid , Preclinical Tumor , Immune Tolerance Breaking Technology , Orphan Drug Designation , Manufacturing Facility ,